In conclusion, patients initiating DPP-4 inhibitors as third-line therapy in type 2 diabetes appeared to have lower discontinuation and have less hypoglycemia when compared to patients starting NPH insulin. The gene discussed is INS; the disease is type 2 diabetes mellitus.